This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Strowski, M. Z. Articles by Schaeffer, J. M. Search for Related Content PubMed PubMed Citation Articles by Strowski, M. Z. Articles by Schaeffer, J. M.

Antidiabetic Activity of a Highly Potent and Selective Nonpeptide Somatostatin Receptor Subtype-2 Agonist

Medizinische Klinik m. S. Hepatologie, Gastroenterologie, Endokrinologie und Stoffwechsel (M.Z.S., V.S.), Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum, 13353 Berlin, Germany; Departments of Animal Pharmacology (D.E.C., T.M.J.), Molecular Endocrinology and Metabolic Disorders, Atherosclerosis and Endocrinology (E.T.B, S.P.R., J.M.S.), and Medicinal Chemistry (L.Y., A.A.P.), Merck Research Laboratories, Rahway, New Jersey 07065; Huffington Center on Aging and Departments of Molecular and Cellular Biology and Medicine (R.G.S.), Baylor College of Medicine, Houston, Texas 77030; and Department of Animal Physiology and Biochemistry (K.W.N.), August Cieszkowski University of Agriculture, 60-637 Poznan, Poland

Address all correspondence and requests for reprints to: Mathias Z. Strowski, M.D., Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum, Medizinische Klinik m. S. Hepatologie, Gastroenterologie, Endokrinologie und Stoffwechsel, Augustenburger Platz 1, 13353 Berlin, Germany. E-mail: mathias.strowski{at}charite.de.

Somatostatin inhibits both glucagon and insulin secretion. Glucagon significantly contributes to hyperglycemia in type 2 diabetes. Despite its function in the inhibition of glucagon secretion, somatostatin fails to reduce hyperglycemia in type 2 diabetes, due to a parallel suppression of insulin secretion. Five pharmacologically distinct somatostatin receptor subtypes (sst₁–sst₅) mediate the effects of somatostatin on a cellular level. Pancreatic A cells express sst₂, whereas B cells express sst₅. In this study, we describe a novel approach to the treatment of type 2 diabetes using a highly sst₂-selective, nonpeptide agonist (compound 1). Compound 1 effectively inhibited glucagon secretion from pancreatic islets isolated from wild-type mice, whereas glucagon secretion from sst₂-deficient islets was not suppressed. Compound 1 did not influence nonfasted insulin concentration. In sst₂-deficient mice, compound 1 did not have any effects on glucagon or glucose levels, confirming its sst₂ selectivity. In animal models of type 2 diabetes in the nonfasted state, circulating glucagon and glucose levels were decreased after treatment with compound 1. In the fasting state, compound 1 lowered blood glucose by approximately 25%. In summary, small-molecule sst₂-selective agonists that suppress glucagon secretion offer a novel approach toward the development of orally bioavailable drugs for treatment of type 2 diabetes.

This article has been cited by other articles:

				E. Tuduri, L. Marroqui, S. Soriano, A. B. Ropero, T. M. Batista, S. Piquer, M. A. Lopez-Boado, E. M. Carneiro, R. Gomis, A. Nadal, et al. Inhibitory Effects of Leptin on Pancreatic {alpha}-Cell Function Diabetes, July 1, 2009; 58(7): 1616 - 1624. [Abstract] [Full Text] [PDF]

				I. Quesada, E. Tuduri, C. Ripoll, and A. Nadal Physiology of the pancreatic {alpha}-cell and glucagon secretion: role in glucose homeostasis and diabetes J. Endocrinol., October 1, 2008; 199(1): 5 - 19. [Abstract] [Full Text] [PDF]

				E. Goncz, M. Z. Strowski, C. Grotzinger, K. W. Nowak, P. Kaczmarek, M. Sassek, S. Mergler, B. F. El-Zayat, M. Theodoropoulou, G. K. Stalla, et al. Orexin-A Inhibits Glucagon Secretion and Gene Expression through a Foxo1-Dependent Pathway Endocrinology, April 1, 2008; 149(4): 1618 - 1626. [Abstract] [Full Text] [PDF]

				V. Singh, C. Grotzinger, K. W. Nowak, S. Zacharias, E. Goncz, G. Pless, I. M. Sauer, I. Eichhorn, B. Pfeiffer-Guglielmi, B. Hamprecht, et al. Somatostatin Receptor Subtype-2-Deficient Mice with Diet-Induced Obesity Have Hyperglycemia, Nonfasting Hyperglucagonemia, and Decreased Hepatic Glycogen Deposition Endocrinology, August 1, 2007; 148(8): 3887 - 3899. [Abstract] [Full Text] [PDF]